EUVIMEDEUVIMED entdecken
Crossref

Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri‐microRNA ‐129 maturation

Cheng Wu, Chunqing Miao, Songlin Zhou, Ping-An Chang, Bin He, Xunrong Zhou, Qingsheng Tang iD

Environmental Toxicology · 2024

DOI: 10.1002/tox.24187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Environmental Toxicology, 2024. Verfasst von Cheng Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Dongtai City People's Hospital, Dongtai, Jiangsu, China. Hauptthemen laut MEDLINE: MicroRNAs, Docetaxel, Prostatic Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: 2020 Jiangsu Vocational College of Medicine Clinical Teaching Base Research and Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of resistance to Docetaxel (DTX) compromises its therapeutic efficacy and worsens the prognosis of prostate cancer (PCa), while the underlying regulatory mechanism remains poorly understood. In this study, METTL14 was found to be upregulated in DTX‐resistant PCa cells and PCa tissues exhibiting progressive disease during DTX therapy. Furthermore, overexpression of METTL14 promoted the development of resistance to DTX in both in vitro and in vivo. Interestingly, it was observed that the hypermethylation of the E2F1 targeting site within DTX‐resistant PCa cells hindered the binding ability of E2F1 to the promoter region of METTL14, thereby augmenting its transcriptional activity. Consequently, this elevated expression level of METTL14 facilitated m6A‐dependent processing of pri‐miR‐129 and subsequently led to an increase in miR‐129‐5p expression. Our study highlights the crucial role of the E2F1‐METTL14‐miR‐129‐5p axis in modulating DTX resistance in PCa, underscoring METTL14 as a promising therapeutic target for DTX‐resistant PCa patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsDocetaxelProstatic NeoplasmsDrug Resistance, NeoplasmEpigenesis, GeneticMethyltransferasesAntineoplastic AgentsMaleHumansCell Line, TumorAnimalsE2F1 Transcription FactorGene Expression Regulation, NeoplasticMiceMice, Nude

Stichwörter der Autor:innen

METTL14docetaxel resistancemiR‐129‐5pprostatic cancer

Substanzen

MicroRNAsDocetaxelMethyltransferasesAntineoplastic AgentsE2F1 Transcription Factor

Autor:innen und Institutionen

  • Department of Urology, Dongtai City People's Hospital, Dongtai, Jiangsu, China.
  • Department of Urology, Dongtai Hospital, the Affiliated Hospital of Jiangsu Vocational College of Medicine, Dongtai, Jiangsu, China.
  • Public Health Section, Dongtai City People's Hospital, Dongtai, Jiangsu, China.

ORCID-Profile: Qingsheng Tang

Förderung

  • 2020 Jiangsu Vocational College of Medicine Clinical Teaching Base Research and Development Project

Zitieren

APA

Wu, C., Miao, C., Zhou, S., Chang, P. A., He, B., Zhou, X., & Tang, Q. (2024). Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri‐microRNA ‐129 maturation. Environmental Toxicology. https://doi.org/10.1002/tox.24187

Vancouver

Wu C, Miao C, Zhou S, Chang PA, He B, Zhou X, et al. Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri‐microRNA ‐129 maturation. Environmental Toxicology. 2024. doi:10.1002/tox.24187

BibTeX
@article{Wu2024,
  author = {Wu, Cheng and Miao, Chunqing and Zhou, Songlin and Chang, Ping-An and He, Bin and Zhou, Xunrong and Tang, Qingsheng},
  title = {Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri‐microRNA ‐129 maturation},
  journal = {Environmental Toxicology},
  year = {2024},
  doi = {10.1002/tox.24187}
}
Kostenlos starten →